Page 30 - Program Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published June 10, 2021, 8:08 PM Hoping to spark the interest of applicant-Overseas Filipino Workers (OFWs) to start their own ventures, the Department of Science and Technology (DOST) conducted a series of pitching sessions showcasing its locally-developed technologies. ‘TeknoLokal para Makabagong Bayani’ aims to encourage OFWs to adopt DOST-developed technologies which will be funded under the Innovations for Filipinos Working Distantly from the Philippines (iFWD PH) Program. (Photo from DOST) DOST on Thursday, June 10, said that its Regional Office I (DOST-I) spearheaded a three-day v...

In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, California, India, and New

Share: In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, California, India, and New York, in Addition to the Previously Reported Varia Ongoing Phase 2 Pilot Study of Ensovibep in Ambulatory Patients Now Expanding Into Second Cohort Two Global Phase 2 and 3 Clinical Studies of Ensovibep on Track for Initiation This Month ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 6, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of cust...

Share: ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. "Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic forming a meaningful change agent for us," said Patrick Amstutz, Ph.D., chief executive officer of Molecular Partners. "Twelve months ago, we were only at the initiating...

(1) ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced today its interim management statement for the period ending March 31, 2021. "Molecular Partners continues to grow and expand the reach of our DARPin® therapeutics platform, with the COVID-19 pandemic forming a meaningful change agent for us," said Patrick Amstutz, Ph.D., chief executive officer of Molecular Partners. "Twelve months ago, we were only at the initiating st...